Argenx SE (ARGX):企業の財務・戦略的SWOT分析

◆英語タイトル:Argenx SE (ARGX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH140762FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Argenx SE (Argenx) is a human antibodies developer. The company offers autoimmunity and oncology products. Its wholly owned product candidates include ARGX-113, ARGX-110, ARGX-117 and ARGX-111. Argenx partnered product candidates are ARGX-109, ARGX-112, ARGX-115 AND ARGX-116. The company offers treatment for T-cell lymphoma, nasopharyngeal cancer, chronic myelogenous leukemia and MET amplified cancer among others. It offers product such as Efgartigimod, Cusatuzumab and candidates to myasthenia gravis immune thromocytopeniapemphigus valgaris chronic auto immune diseases, T cell lymphoma, acute myeloid leukemia and blood cancer. Argenx products are used for the treatment of inflammatory and autoimmune diseases. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands and Belgium. Argenx is headquartered in Breda, the Netherlands.

Argenx SE Key Recent Developments

Mar 04,2021: argenx reports full year 2020 financial results and provides fourth quarter business update
Mar 04,2021: argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update argenx today reported financial results for the full year 2020 and provided a fourth quarter business update. Read
Feb 04,2021: argenx announces full exercise of underwriters option to purchase additional ADSs
Jan 11,2021: argenx to Present at 39th Annual J.P. Morgan Healthcare Conference argenx today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 a.m. ET. Re
Jan 07,2021: L2 : Business Expansions : argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China argenx SE and Zai Lab Limited today announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater Read

This comprehensive SWOT profile of Argenx SE provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Argenx SE including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Argenx SE – Key Information
Argenx SE – Overview
Argenx SE – Key Employees
Argenx SE – Key Employee Biographies
Argenx SE – Key Operational Heads
Argenx SE – Major Products and Services
Argenx SE – History
Argenx SE – Company Statement
Argenx SE – Locations And Subsidiaries
Argenx SE
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Argenx SE – Business Description
Argenx SE – Corporate Strategy
Argenx SE – SWOT Analysis
SWOT Analysis – Overview
Argenx SE – Strengths
Argenx SE – Weaknesses
Argenx SE – Opportunities
Argenx SE – Threats
Argenx SE – Key Competitors

Section 3 – Company Financial Performance Charts

Argenx SE – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Argenx SE, Key Information
Argenx SE, Key Ratios
Argenx SE, Share Data
Argenx SE, Major Products and Services
Argenx SE, History
Argenx SE, Key Employees
Argenx SE, Key Employee Biographies
Argenx SE, Key Operational Heads
Argenx SE, Other Locations
Argenx SE, Subsidiaries
Argenx SE, Key Competitors
Argenx SE, SWOT Analysis
Argenx SE, Ratios based on current share price
Argenx SE, Annual Ratios
Argenx SE, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Argenx SE (ARGX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Armstrong World Industries Inc (AWI):企業の財務・戦略的SWOT分析
    Armstrong World Industries Inc (AWI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Thien Viet Securities Joint Stock Company:企業の戦略的SWOT分析
    Thien Viet Securities Joint Stock Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • ReCor Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary ReCor Medical Inc (ReCor Medical), a subsidiary of Otsuka Holdings Co Ltd, is a medical device company that designs and manufactures a proprietary ultrasound ablation system for performing renal denervation. The company develops paradise renal denervation system, a therapeutic non-focused ul …
  • Zimmer Biomet Holdings Inc (ZBH)-製薬・医療分野:企業M&A・提携分析
    Summary Zimmer Biomet Holdings Inc (Zimmer Biomet) is a medical device company with focus on musculoskeletal healthcare. It carries out the design, development, manufacture, and marketing of reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, cr …
  • Ingram Micro Inc.:企業の戦略的SWOT分析
    Ingram Micro Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Spectris Plc (SXS):企業の財務・戦略的SWOT分析
    Spectris Plc (SXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • U.S. Stem Cell Inc (USRM):企業の財務・戦略的SWOT分析
    U.S. Stem Cell Inc (USRM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Insperity, Inc. (NSP):企業の財務・戦略的SWOT分析
    Insperity, Inc. (NSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Frisch’s Restaurants, Inc.:戦略・SWOT・企業財務分析
    Frisch's Restaurants, Inc. - Strategy, SWOT and Corporate Finance Report Summary Frisch's Restaurants, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Deutsche Bahn AG:企業の戦略・SWOT・財務情報
    Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Miele & Cie. KG:企業の戦略的SWOT分析
    Miele & Cie. KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • XL-protein GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary XL-protein GmbH (XL-protein) is a biopharmaceutical company that develops second generation biopharmaceutical drugs. The company develops PASylation technology, designed to enable the biopharmaceuticals drug development with extended plasma half-life and enhanced action. It provides its tech …
  • Les Laboratoires Servier SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Les Laboratoires Servier SAS (Servier) researches, develops, manufactures and markets drugs for treating various diseases. The company's portfolio of marketed products treat central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, women's …
  • Main Line Health System:企業の戦略的SWOT分析
    Main Line Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Interprotein Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Interprotein Corp (Interprotein) is a drug development company that develops active modulators for protein-protein interaction (PPI) targets. The company offers products such as IL-6 inhibitor, IgE inhibitor, notch1 inhibitor, tubulin polymerization inhibitors, TIM-3 inhibitor, NKG2A, HLA-E …
  • Airservices Australia:企業の戦略的SWOT分析
    Airservices Australia - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Volta River Authority:企業の戦略的SWOT分析
    Volta River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • American Airlines Group Inc (AAL):企業の財務・戦略的SWOT分析
    American Airlines Group Inc (AAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Xcel Energy Inc (XEL)-エネルギー分野:企業M&A・提携分析
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • China Overseas Land & Investment Limited:企業の戦略・SWOT・財務情報
    China Overseas Land & Investment Limited - Strategy, SWOT and Corporate Finance Report Summary China Overseas Land & Investment Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆